Leading its way through the growing market of Urology, Boston Scientific CorporationBSX has recently entered into an agreement to buy Minnesota-based NxThera for a deal value of up to $406 million.

WAYNE, Pa., June 22, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced the publication of data from a study comparing patient experience of those treated with the UroLift ® ...

Bipolar androgen therapy may benefit some men with asymptomatic CRPC who have a low to moderate meta By 3 and 6 months, flow rate, post void residual, IPSS, quality of life, and prostate volume ...

Boston Scientific officially acquired NxThera, the company behind the Rezum system. Here’s what you should know. 1. The Rezum system is a minimally invasive therapy for patients with symptomatic ...